22556 Federal Register / Vol. 80, No. 77 / Wednesday, April 22, 2015 / Notices 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

redelegated to the Deputy Assistant 

Administrator of the DEA Office of 

Diversion Control (‘‘Deputy Assistant 

Administrator’’) pursuant to section 7 of 

28 CFR part 0, appendix to subpart R. 

In accordance with 21 CFR 

1301.33(a), this is notice that on May 15, 

2014, Cambrex Charles City, 1205 11th 

Street, Charles City, Iowa 50616 applied 

to be registered as a bulk manufacturer 

the following basic classes of controlled 

substances: 

Controlled substance Schedule 

Amphetamine (1100) .................... II 

Lisdexamfetamine (1205) ............. II 

Methylphenidate (1724) ................ II 

4-Anilino-N-phenethyl-4-piperidine 

(8333).

II 

Phenylacetone (8501) .................. II 

Cocaine (9041) ............................. II 

Codeine (9050) ............................. II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Hydrocodone (9193) ..................... II 

Morphine (9300) ........................... II 

Oripavine (9330) ........................... II 

Thebaine (9333) ........................... II 

Opium, raw (9600) ....................... II 

Opium extracts (9610) .................. II 

Opium fluid extract (9620) ............ II 

Opium tincture (9630) .................. II 

Opium, powdered (9639) ............. II 

Opium, granulated (9640) ............ II 

Oxymorphone (9652) ................... II 

Noroxymorphone (9668) .............. II 

Poppy Straw Concentrate (9670) II 

Alfentanil (9737) ........................... II 

Remifentanil (9739) ...................... II 

Sufentanil (9740) .......................... II 

Fentanyl (9801) ............................ II 

The company plans to manufacture 

the listed controlled substances in bulk 

for sale to its customers, for dosage form 

development, for clinical trials, and for 

use in stability qualification studies. 

Dated: April 14, 2015. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator. 

[FR Doc. 2015–09325 Filed 4–21–15; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Importer of Controlled Substances 

Application: Rhodes Technologies 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration in 

accordance with 21 CFR 1301.34(a) on 

or before May 22, 2015. Such persons 

may also file a written request for a 

hearing on the application pursuant to 

21 CFR 1301.43 on or before May 22, 

2015. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/ODXL, 8701 

Morrissette Drive, Springfield, Virginia 

22152. Request for hearings should be 

sent to: Drug Enforcement 

Administration, Attention: Hearing 

Clerk/LJ, 8701 Morrissette Drive, 

Springfield, Virginia 22152. Comments 

and request for hearings on applications 

to import narcotic raw material are not 

appropriate. 72 FR 3417 (January 25, 

2007). 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

redelegated to the Deputy Assistant 

Administrator of the DEA Office of 

Diversion Control (‘‘Deputy Assistant 

Administrator’’) pursuant to section 7 of 

28 CFR part 0, appendix to subpart R. 

In accordance with 21 CFR 

1301.34(a), this is notice that on March 

10, 2015, Rhodes Technologies, 498 

Washington Street, Coventry, Rhode 

Island 02816 applied to be registered as 

an importer of the following basic 

classes of controlled substances: 

Controlled Substance Schedule 

Opium, raw (9600) ....................... II 

Poppy Straw Concentrate (9670) II 

The company plans to import the 

listed controlled substances in order to 

bulk manufacture controlled substances 

in Active Pharmaceutical Ingredient 

(API) form. The company distributes the 

manufactured APIs in bulk to its 

customers. 

Dated: April 14, 2015. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator. 

[FR Doc. 2015–09338 Filed 4–21–15; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Importer of Controlled Substances 

Application: Almac Clinical Services 

Inc. (ACSI) 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration in 

accordance with 21 CFR 1301.34(a) on 

or before May 22, 2015. Such persons 

may also file a written request for a 

hearing on the application pursuant to 

21 CFR 1301.43 on or before May 22, 

2015. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/ODXL, 8701 

Morrissette Drive, Springfield, Virginia 

22152. Request for hearings should be 

sent to: Drug Enforcement 

Administration, Attention: Hearing 

Clerk/LJ, 8701 Morrissette Drive, 

Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

redelegated to the Deputy Assistant 

Administrator of the DEA Office of 

Diversion Control (‘‘Deputy Assistant 

Administrator’’) pursuant to section 7 of 

28 CFR part 0, appendix to subpart R. 

In accordance with 21 CFR 

1301.34(a), this is notice that on March 


asabaliauskas on DSK5VPTVN1PROD with NOTICES
Federal Register / Vol. 80, No. 77 / Wednesday, April 22, 2015 / Notices 22557 

5, 2015, Almac Clinical Services Inc., 

(ACSI), 25 Fretz Road, Souderton, 

Pennsylvania 18964 applied to be 

registered as an importer of the 

following basic classes of controlled 

substances: 

Controlled substance Schedule 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Tapentadol (9780) ........................ II 

Fentanyl (9801) ............................ II 

The company plans to import small 

quantities of the listed controlled 

substances in dosage form to conduct 

clinical trials. 

Dated: April 14, 2015. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator. 

[FR Doc. 2015–09333 Filed 4–21–15; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Bulk Manufacturer of Controlled 

Substances Application: Sigma Aldrich 

Research Biochemicals, Inc. 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration in 

accordance with 21 CFR 1301.33(a) on 

or before June 22, 2015. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/ODXL, 8701 

Morrissette Drive, Springfield, Virginia 

22152. Request for hearings should be 

sent to: Drug Enforcement 

Administration, Attention: Hearing 

Clerk/LJ, 8701 Morrissette Drive, 

Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

redelegated to the Deputy Assistant 

Administrator of the DEA Office of 

Diversion Control (‘‘Deputy Assistant 

Administrator’’) pursuant to section 7 of 

28 CFR part 0, appendix to subpart R. 

In accordance with 21 CFR 

1301.33(a), this is notice that on January 

2, 2015, Sigma Aldrich Research 

Biochemicals, Inc., 1–3 Strathmore 

Road, Natick, Massachusetts 01760– 

2447 applied to be registered as a bulk 

manufacturer of the following basic 

classes of controlled substances: 

Controlled substance Schedule 

Cathinone (1235) .......................... I 

Methcathinone (1237) .................. I 

Mephedrone (4-Methyl-Nmethylcathinone) (1248).I 

Aminorex (1585) ........................... I 

Alpha-ethyltryptamine (7249) ....... I 

Lysergic acid diethylamide (7315) I 

Tetrahydrocannabinols (7370) ..... I 

4-Bromo-2,5- 

dimethoxyamphetamine (7391).

I 

4-Bromo-2,5- 

dimethoxyphenethylamine 

(7392).

I 

4-Methyl-2,5- 

dimethoxyamphetamine (7395).

I 

2,5-Dimethoxyamphetamine 

(7396).

I 

3,4-Methylenedioxyamphetamine 

(7400).

I 

N-Hydroxy-3,4- 

methylenedioxyamphetamine 

(7402).

I 

3,4-Methylenedioxy-Nethylamphetamine (7404).I 

3,4- 

Methylenedioxymethamphetamine (7405).

I 

Dimethyltryptamine (7435) ........... I 

Psilocybin (7437) .......................... I 

5-Methoxy-N,Ndiisopropyltryptamine (7439).I 

1-[1-(2- 

Thienyl)cyclohexyl]piperidine 

(7470).

I 

N-Benzylpiperazine (7493) ........... I 

MDPV (3,4- 

Methylenedioxypyrovalerone) 

(7535).

I 

Methylone (3,4-Methylenedioxy-Nmethylcathinone).

(7540) ........................................... I 

Heroin (9200) ............................... I 

Normorphine (9313) ..................... I 

Amphetamine (1100) .................... II 

Methamphetamine (1105) ............ II 

Nabilone (7379) ............................ II 

1-Phenylcyclohexylamine (7460) II 

Phencyclidine (7471) .................... II 

Cocaine (9041) ............................. II 

Codeine (9050) ............................. II 

Ecgonine (9180) ........................... II 

Levomethorphan (9210) ............... II 

Levorphanol (9220) ...................... II 

Meperidine (9230) ........................ II 

Metazocine (9240) ........................ II 

Methadone (9250) ........................ II 

Morphine (9300) ........................... II 

Thebaine (9333) ........................... II 

Controlled substance Schedule 

Levo-alphacetylmethadol (9648) .. II 

Remifentanil (9739) ...................... II 

Sufentanil (9740) .......................... II 

Carfentanil (9743) ......................... II 

Fentanyl (9801) ............................ II 

The company plans to manufacture 

reference standards. 

Dated: April 14, 2015. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator. 

[FR Doc. 2015–09328 Filed 4–21–15; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Bulk Manufacturer of Controlled 

Substances Application: Cayman 

Chemicals Company 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration in 

accordance with 21 CFR 1301.33(a) on 

or before June 22, 2015. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/ODXL, 8701 

Morrissette Drive, Springfield, Virginia 

22152. Request for hearings should be 

sent to: Drug Enforcement 

Administration, Attention: Hearing 

Clerk/LJ, 8701 Morrissette Drive, 

Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

redelegated to the Deputy Assistant 

Administrator of the DEA Office of 

Diversion Control (‘‘Deputy Assistant 

Administrator’’) pursuant to section 7 of 

28 CFR part 0, appendix to subpart R. 

In accordance with 21 CFR 

1301.33(a), this is notice that on July 24, 

2014, Cayman Chemical Company, 1180 


asabaliauskas on DSK5VPTVN1PROD with NOTICES